<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR1">
 <label>1.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Topp</surname>
    <given-names>MS</given-names>
   </name>
   <name>
    <surname>Gokbuget</surname>
    <given-names>N</given-names>
   </name>
   <name>
    <surname>Stein</surname>
    <given-names>AS</given-names>
   </name>
   <name>
    <surname>Zugmaier</surname>
    <given-names>G</given-names>
   </name>
   <name>
    <surname>O'Brien</surname>
    <given-names>S</given-names>
   </name>
   <name>
    <surname>Bargou</surname>
    <given-names>RC</given-names>
   </name>
   <name>
    <surname>Dombret</surname>
    <given-names>H</given-names>
   </name>
   <name>
    <surname>Fielding</surname>
    <given-names>AK</given-names>
   </name>
   <name>
    <surname>Heffner</surname>
    <given-names>L</given-names>
   </name>
   <name>
    <surname>Larson</surname>
    <given-names>RA</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study</article-title>
  <source>Lancet Oncol</source>
  <year>2015</year>
  <volume>16</volume>
  <issue>1</issue>
  <fpage>57</fpage>
  <lpage>66</lpage>
  <pub-id pub-id-type="doi">10.1016/S1470-2045(14)71170-2</pub-id>
  <?supplied-pmid 25524800?>
  <pub-id pub-id-type="pmid">25524800</pub-id>
 </element-citation>
</ref>
